Morrisons Plans to Shut Around 100 Stores Amid Rising Cost Pressures Subramanian Swamy Calls for Ban on Cement Imports from Pakistan Over Security Concerns US GDP Growth for Q1 2026 Revised Lower to 16 Amid Slowing Corporate Profits Inflation Expected to Reach 6 in Q2 Economists Warn Trump Signals Desire for New Fed Chair to Operate With Full Independence IEA Chief Warns Oil Markets May Enter Red Zone by MidSummer Amid Iran Crisis MNR Q1 2026 Earnings Significant EPS Miss Amid Challenging Commodity Environment SIRI Q1 2026 Earnings EPS Surpasses Estimates Yet Stock Declines Polaris Inc PII Q1 2026 Earnings Strong EPS Beat Drives Positive Sentiment After Challenging Quarter CVKD Q1 2026 Earnings NarrowerthanExpected Loss as PreRevenue Biotech Advances Pipeline BGS Q1 2026 Earnings Earnings Beat Driven by Cost Discipline and Portfolio Optimization YETI Q1 2026 Earnings Strong EPS Beat Drives Stock Higher Energy Focus EFOI Inches Higher Testing Key Resistance Near 409 Sound Point Meridian Capital Preferred Shares SPMA Edge Lower as Trading Remains RangeBound Neuberger Energy Infrastructure Fund NML Pulls Back Testing Key Support Levels Enova International ENVA Declines 175 as Stock Holds Between Key Support and Resistance Ardent Health ARDT Holds Near Support as Slight Gain Marks Cautious Session Golds Risk Premium Appears Compressed Suggesting Limited Upside Potential in Near Term COLD Q1 2026 Earnings EPS Surprises to the Upside as Loss Narrows Aurinia Pharmaceuticals AUPH Treads at 1522 as Shares Dip Support and Resistance in Focus PCB Bancorp Q1 2026 Earnings Strong EPS Beat Belies Quiet Market Reception MMSI Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response Embecta Corp EMBC Q1 2026 Earnings EPS Misses Expectations as Revenue Data Remains Unavailable Definitive Healthcare Corp DH Q1 2026 Earnings EPS Surge Beats Expectations Stock Climbs Catalyst Pharmaceuticals CPRX Q1 2026 Earnings EPS Beat Signals Operational Strength Amid Quiet Revenue Reporting IIIN Q1 2026 Earnings EPS Misses Estimates by Wide Margin Amid Challenging Conditions Altimmune Q1 2026 Earnings Narrower Loss Surprises Amid Ongoing Clinical Focus